Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

19 results about "Cladribine" patented technology

Cladribine is used to treat a certain type of cancer (hairy cell leukemia).

Methods and materials for treating hyperoxalemia and / or hyperoxaluria

PCT designated stage expiredWO2025075711A1Organic active ingredientsMetabolism disorderPyridostigmineProteases
This document provides methods and materials for treating hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease). For example, methods and materials for using one or more compounds that can activate oxalate transport to treat a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) are provided. In some cases, one or more of atorvastatin, cinacalcet, cyproheptadine, vortioxetine, pizotifen, ritonavir, dronedarone, thioridazine, nilotinib, bexarotene, mebendazole, racecadotril, pefloxacin, cabazitaxel, oxibendazole, pyridostigmine, olanzapine, trifluoperazine, AZ-5104, centrimonium, cladribine, ponatinib, dasatinib, and erlotinib can be administered to a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) to treat the mammal.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Use of cladrabine in the preparation of a medicament for inhibiting the growth of multi-drug resistant klebsiella pneumoniae

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Identifying disease-specific eyeball movement patterns using visual stimulation, drugs, or treatments

Systems and methods are provided that assess eye movement in multiple sclerosis (MS) patients receiving different drugs (e.g., dimethyl fumarate, fingolimod, clababine, ofarmumab) or treatments that (a) alleviate inflammation that may cause a symptom of multiple sclerosis and prevent nerve injury that may cause a symptom of multiple sclerosis); (b) testing sphingosine-1-phosphate receptor modulators that chelate lymphocytes in the lymphocyte nodes, preventing them from causing an autoimmune response); (c) checking for immunosuppressants acting on the lymphocyte pathway); and (d) analyzing the effect of the monoclonal antibody in inhibiting activation of lymphocyte B.
Owner:THINKING CO LTD

Cladribine regimen for treating myasthenia gravis

The present invention relates to compounds for the treatment of Myasthenia Gravis and related methods and dosing regimen. Specifically, the invention pertains to the field of treatment scheme of oral formulation of cladribine and relevant for the treatment of Myasthenia Gravis, more specifically generalized Myasthenia Gravis.
Owner:ARES TRADING SA

Use of cladribine for treating autoimmune neuromuscular disease

ActiveUS12171775B2Organic active ingredientsMuscular disorderChlorodeoxyadenosineDisease
The present invention relates to the use of 2-chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).
Owner:CHORD THERAPEUTICS SARL

Use of cladribine for treating autoimmune neuromuscular disease

PendingUS20250302858A1Organic active ingredientsMuscular disorderChlorodeoxyadenosineDisease
The present invention relates to the use of 2-chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).
Owner:CHORD THERAPEUTICS SARL

Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases

A transmucosal delivery composition in form of a sublingual orally dispersible film comprising cladribine as active ingredient and comprising at least two hydrophilic polymers, wherein the at least two hydrophilic polymers represent at least 20% (w / w) of the total composition, wherein cladribine is contained in the composition as a cladribine-cyclodextrin complex. Said composition for use in the treatment of multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorders (NMOSD). A method for producing a transmucosal delivery composition in form of a sublingual orally dispersible film, wherein cladribine or cladribine-cyclodextrin complex is mixed with film-forming polymers by stirring with at least 100 rpm for at least 10 min at a temperature of at least 30° C.
Owner:VEKTOR PHARMA TF GMBH

Cladribine regimen for treating multiple sclerosis

InactiveEP4523753A3Organic active ingredientsNervous disorderRegimenSecondary progressive multiple sclerosis
The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Owner:MERCK SERONO SA

Method of production of cladribine

PCT designated stageWO2025242248A1Sugar derivativesFermentationEnzymatic synthesisPurine nucleoside phosphorylase
The invention relates to a method of producing cladribine with a purity greater than 99.9 wt.% from 2-deoxyuridine and 2-chloroadenine by using the catalytic action of high concentrations (at least 20.000 U / L) of freely dissolved transglycosidases UP (uridine phosphorylase) and PNP (purine nucleoside phosphorylase) in an enzymatic synthesis in an aqueous environment without the presence of any organic solvent.
Owner:VUAB PHARMA AS

Cladribine regimen for treating progressive forms of multiple sclerosis

ActiveUS12268703B2Organic active ingredientsNervous disorderProgressive multiple sclerosisRegimen
Specific oral dosings, specific oral dosage forms, and / or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and / or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and / or specific oral dose regimens including Cladribine.
Owner:ARES TRADING SA

Cladribine regimen for treating progressive forms of multiple sclerosis

Specific oral dosings, specific oral dosage forms, and / or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and / or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and / or specific oral dose regimens including Cladribine.
Owner:ARES TRADING SA

Clartrobine therapy for treatment of progressive forms of multiple sclerosis

PendingCN119097635AHigh disease activityOrganic active ingredientsNervous disorderOral medicationSecondary progressive multiple sclerosis
The present invention relates to a clavabine therapy for the treatment of progressive forms of multiple sclerosis. In particular, the present invention relates to the use of specific oral doses, specific oral dosage forms and / or specific oral administration methods comprising clathrabine for the treatment of progressive forms of multiple sclerosis, in particular primary progressive multiple sclerosis and / or secondary progressive multiple sclerosis, as well as methods of treatment based thereon.
Owner:MERCK PATENT GMBH